Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04079517
Other study ID # 2015-000345
Secondary ID 2014-005005-20
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date March 2015
Est. completion date March 2016

Study information

Verified date September 2019
Source Karolinska Institutet
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A feasibility study, randomising to either 10 or 20 mg of tamoxifen. The primary aim is to identify the time to mammographic density change and piloting the procedures. It is known that a density change is seen after 12 months of 20 mg of tamoxifen, but the clinical experience indicates that an effect of drugs influencing mammographic density could be seen already after a few months. The second aim is to evaluate if there is a density change from 10 mg of tamoxifen equivalent to 20 mg.


Description:

The investigators want to conduct a feasibility study including 42 women who will be randomised to either 10 or 20 mg of daily oral tamoxifen. The primary aim of the study is to identify the time to mammographic density change and piloting the procedures. It is known that a density change is seen after 12 months of 20 mg of daily tamoxifen, but the clinical experience indicates that an effect of drugs influencing mammographic density could be seen already after a few months. The second aim of the pilot study is to see if there is a density change from 10 mg of tamoxifen equivalent to 20 mg and if there is a difference in adverse reactions between the two doses. Interim analysis will be performed at 6 months, monitoring both safety and level of mammographic density change.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date March 2016
Est. primary completion date February 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 40 Years to 74 Years
Eligibility Inclusion Criteria:

- Previously participated in the Karma study

- Attending the national mammography screening program, i.e. aged 40-74

- A mammogram, including a stored raw image, must have been taken within 3 weeks of baseline and start of therapy

- Having a mammographic volumetric density above the lowest 1/6, measured by Volpara

- Informed consent must be signed before any study specific assessments have been performed

Exclusion Criteria:

- Being pregnant or planning to become pregnant during the study

- Any previous or current diagnosis of breast cancer (including carcinoma in situ)

- Recalled (mammographic code 3 or above) after baseline screening mammography

- Any previous diagnosis of cancer, with the exception of non-melanoma skin cancer and in situ cancer of the cervix

- Currently using oestrogen and progesterone-based hormone replacement therapy

- Current use of hormone contraceptive with hormones, e.g. hormonal contraceptive pills, or progesterone implants. Hormonal intrauterine devices are accepted.

- A history of thromboembolic disease such as embolism, deep vein thrombosis, stroke, TIA or cardiac arrest.

- A history of immobilization, e.g. using wheelchair

- Uncontrolled diabetes defined as known untreated diabetes

- Hypertension at baseline, defined as systolic pressure higher than 140 mm Hg and diastolic higher than 90 mm Hg

- Use of drugs that interfere with CYP2D6 expression such as paroxetine, fluoxetine and bupropion

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tamoxifen
A registered SERM drug, Tamoxifen.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Karolinska Institutet

Outcome

Type Measure Description Time frame Safety issue
Primary Time to mammographic density change Mammographic density followed on repeated mammographies by measurements using STRATUS software Mammography after 0, 3, 6, 9 months
Secondary Differences in density change with tamoxifen 10 mg and 20 mg Determine any differences in density change comparing 10 mg and 20 mg of daily oral tamoxifen. Mammography after 0, 3, 6 months
Secondary Differences in and adverse events with tamoxifen 10 mg and 20 mg Determine any differences in adverse events comparing 10 mg and 20 mg of daily oral tamoxifen. Questionnaires after 0, 1, 3, 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A